Wednesday, March 17, 2010
Sign up to receive our free report:
The biggest biotech trends in the market right now
E-mail address:

The business of miracle drugs, cancer cures, and magic pills – biotechnology – is a good friend to seasoned stock traders.

Almost no other sector offers such explosive potential to ring up hundreds of percent gains in just months.

Like every riskier sector, biotech was hammered during the 2008-2009 credit crunch. But the past seven months have produced several successful biotech stories... and investor interest is returning.

That's why The Daily Crux sat down with Rob Fannon, biotech expert, graduate of the Johns Hopkins school of Public Health, and editor of the biotech-focused advisory Phase 1 Investor.

For a road map to trading and investing in the biotech sector for the next several years, sign up and get the details on The biggest biotech trends in the market right now.

E-mail address:

When you sign up for this free report, you'll also receive The Daily Crux Home Delivery.

Each day, the Crux team sifts through the top financial newspapers, magazines, journals, newsletters, blogs, shareholder letters, and research reports. We select only the most valuable news, ideas, and opinions for inclusion on the Crux website. Home Delivery puts it all in your inbox.

E-mail address:
No spam pledge: While we'll occasionally send you information about research we think you might be interested in, we will never rent or sell your e-mail address to anyone for any reason.
©2009 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This website may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202.